Despasm 135 Uses
Despasm 135 is indicated for the symptomatic treatment
of irritable bowel syndrome and other conditions
usually included in this grouping, such as:
chronic irritable colon, mucous colitis, spastic colitis
and spastic constipation.
Despasm 135 is used to treat irritable bowel syndrome (disorder of the intestines that leads to cramps in the abdomen, gas, bloating and changes in bowel habits). It is also used to treat other conditions that involve spasm and pain related to small and large bowel.
Each Despasm 135 tablet also contains the following excipients: Tablet Core: Lactose monohydrate, starch (potato), povidone, talc, magnesium stearate. Tablet Coating: Talc, sucrose, gelatine, acacia, canuba wax.
Each Despasm 135 Retard prolonged-release capsule also contains the following excipients: Magnesium stearate, copolymer of ethyl acrylate and methyl methacrylate, talc, methylhydroxypropylcellulose, methacrylic acid-ethyl acrylate copolymer (1:1) and glycerol.
Adult: Despasm 135: 1 tablet thrice daily, taken approximately 20 min before meals.
The physician will advice the patient on the duration of use of Despasm 135. Duration of use is not limited, however, after a period of several weeks when the desired effect has been obtained, the dosage may be gradually reduced.
Missed Dose: If ≥1 dose is missed, continue with the next dose as prescribed. Do not take the missed dose(s) in addition to the regular dose.
Despasm 135 Retard: 1 capsule twice daily, to be given in the morning and evening.
Administration: The tablet/capsule should be swallowed with at least 100 mL (Despasm 135) water and should not be chewed because of the unpleasant taste.
Despasm 135: Tell the physician or pharmacist if taking or have recently taken any other medicines including medicines obtained without a prescription.
Interaction studies have only been performed with alcohol. In vitro and in vivo studies in animals have shown no significant interaction between Despasm 135 and ethanol. No other interaction studies have been performed.
Incompatibilities: Not applicable.
In therapeutic doses, no adverse effects have
been reported. Rarely allergic reactions (including
rash, urticaria, angioedema), could be noticed.
USE DURING PREGNANCY AND LACTATION:
Animal experiments have failed to show any teratogenic
effects. However, administration of Despasm 135
is to be discouraged during pregnancy.
Despasm 135 is not excreted in the milk of lactating
women after therapeutic doses.
For both cases, the medicine should be used with
No contraindications have been reported.
Despasm 135 does not provoke any atropinic effect and for this reason is not contraindicated in patients with glaucoma or prostatic hypertrophy.
List of Despasm 135 substitutes (brand and generic names)
|Sort by popularity|
|Unit description / dosage (Manufacturer)||Price, USD|
|Colofac/Colofac Retard (Thailand)|
|Colofac Retard PR cap 200 mg 30's (Abbott)|
|Colofac tab 135 mg 50's (Abbott)|
|Duspatalin 杜適林 (Hongkong)|
|Mebeverine HCl (Singapore)|
|Mevrin 135 (Myanmar)|
|Mevrin 135 tab 40's (S.J. & G. Fazul Ellahie)|
|Vermeb 135 mg x 5 Blister x 10 Tablet|
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology